Purple Biotech (PPBT) Debt to Equity (2017 - 2020)

Purple Biotech (PPBT) has 4 years of Debt to Equity data on file, last reported at $0.43 in Q2 2020.

• Debt to Equity for Q2 2020 came in at $0.43, up 102.83% year-over-year; the trailing twelve-month figure through Jun 2020 was $0.43 (up 102.83% YoY), and the FY2018 annual result was $0.05, down 78.26% from the prior year.
• Debt to Equity climbed to $0.43 in Q2 2020 per PPBT's latest filing, from $0.21 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.43 in Q2 2020 and troughed at $0.05 in Q4 2018.
• A 4-year average of $0.24 and a median of $0.22 in 2019 frame the typical range for Debt to Equity.
• On a YoY basis, Debt to Equity climbed as much as 405.06% in 2018 and fell as far as 78.26% in 2018.
• A 4-year view of Debt to Equity shows it stood at $0.23 in 2017, then sank by 78.26% to $0.05 in 2018, then surged by 325.63% to $0.21 in 2019, then soared by 102.83% to $0.43 in 2020.
• Business Quant data shows PPBT's Debt to Equity at $0.43 in Q2 2020, $0.21 in Q2 2019, and $0.05 in Q4 2018.